Safety and Preliminary Efficacy Study of EE001 in Health/Patients Adults with Mild, Moderate, or Severe (NYHA II-IV) Cardiac Insufficiency

NCT06884111 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Cardiac Insufficiency

Interventions

DRUG: EE001，70-105ml per day by IV

Sponsor

Anhui HygeianCells BioMedical Co., Ltd.